IcanoMAB

Executive Summary

IcanoMAB is a private German biotechnology company developing precision canonical signaling monoclonal antibodies for oncology, immunology, and acute inflammatory diseases, including severe COVID-19 complications. The company's pipeline comprises three advanced preclinical candidates in-licensed from MAB Discovery GmbH. IcanoMAB's approach targets specific signaling pathways to improve therapeutic outcomes while minimizing off-target effects. Despite being at the preclinical stage, the company has secured key assets and operates in high-demand therapeutic areas. The near-term focus is on advancing these candidates toward IND-enabling studies and establishing strategic partnerships to support clinical development.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Candidate40% success
• Q3 2026Partnership or Licensing Deal50% success
• Q3 2026Preclinical Data Presentation at Scientific Conference70% success